摘要
目的分析老年慢性肾脏病(chronic kidney disease,CKD)患者使用肾康注射液的疗效和安全性。方法对2007年10月～2009年2月在解放军总医院住院并使用肾康注射液的76例老年CKD患者的临床资料进行回顾性分析,分析患者使用肾康注射液治疗前后的肝肾功能、血脂谱、凝血功能等指标的变化。结果应用肾康注射液的老年CKD患者的平均年龄84.37±5.98岁,平均病程5.74±4.45年。采用肾康注射液治疗后,平均血肌酐下降18.42±31.67μmol/l,尿素氮下降1.35±2.74mmol/L;治疗后63例(82.89%)血肌酐有下降,其中显效8例(10.53%),有效24例(31.58%),无效31例(40.79%),13例血肌酐有不同程度的升高(17.11%);治疗疗程0.5个月和1个月相比,血肌酐水平的降低差异无统计学意义(P>0.05);肾康注射液是否同时合用前列地尔注射液在治疗后两组间疗效和血肌酐降幅差异无统计学意义(P>0.05);CKD5期疗效>4期>3期。治疗前后患者的血脂水平、凝血功能及肝功能指标差异均无统计学意义(P>0.05)。76例患者在治疗期间均无明显不良反应记录。结论老年CKD3～5期患者应用肾康注射液治疗可以显著降低血肌酐水平,且安全性较好。
Objective To evaluate the safety and efficacy of Shenkang injection in treatment of ageing with chronic kidney disease（CKP）. Methods Seventy-six elderly cases with CKD were reviewed,the changes in liver and renal function,blood fat, and blood coagulation were rcvaluated before and after treatment. Results The level of serum creatinine and urea nitrogen significantly reduced after treatment. There was no significant diffenrence between one month treatment and half month treatment. Treatment whether combined with Alprostadil or not had no difference. Liver function,blood fat,blood coagulation had no significant change after treatment. 76 cases had none adverse effect. Conclusions Shenkang injection can significantly reduce the level of serum creatinine in CKD patient at stage 3-5,and it is safe.
出处
《中华保健医学杂志》
2010年第2期97-99,共3页
Chinese Journal of Health Care and Medicine
关键词
慢性肾脏病
肾康注射液
老年
Chronic Kidney Disease
Shenkang injection
Ageing
